Education
About Us
Working with TipRanks
Follow Us
Captor Therapeutics SA (PL:CTX)
STUTTGART:CTX
CTX Stock Chart & Stats
zł42.20
--
Market closed
zł42.20
--
Day’s Range― - ―
52-Week Rangezł31.20 - zł84.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)15.34K
Market Cap
zł464.41M
Enterprise Valuezł191.20M
Total Cash (Recent Filing)zł35.97M
Total Debt (Recent Filing)zł3.82M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Apr 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding5,528,709
10 Day Avg. Volume10,947
30 Day Avg. Volume15,340
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.06
Price to Sales (P/S)12.45
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-26.78
Revenue Forecast (FY)zł86.16M
CTX FAQ
What was Captor Therapeutics SA’s price range in the past 12 months?
Captor Therapeutics SA lowest stock price was zł31.20 and its highest was zł84.80 in the past 12 months.
What is Captor Therapeutics SA’s market cap?
Captor Therapeutics SA’s market cap is zł464.41M.
When is Captor Therapeutics SA’s upcoming earnings report date?
Captor Therapeutics SA’s upcoming earnings report date is Apr 02, 2026 which is in 80 days.
How were Captor Therapeutics SA’s earnings last quarter?
Captor Therapeutics SA released its earnings results on Nov 20, 2025. The company reported -zł2.076 earnings per share for the quarter, missing the consensus estimate of N/A by -zł2.076.
Is Captor Therapeutics SA overvalued?
According to Wall Street analysts Captor Therapeutics SA’s price is currently Overvalued.
Does Captor Therapeutics SA pay dividends?
Captor Therapeutics SA does not currently pay dividends.
What is Captor Therapeutics SA’s EPS estimate?
Captor Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Captor Therapeutics SA have?
Captor Therapeutics SA has 5,528,709 shares outstanding.
What happened to Captor Therapeutics SA’s price movement after its last earnings report?
Captor Therapeutics SA reported an EPS of -zł2.076 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.391%.
Which hedge fund is a major shareholder of Captor Therapeutics SA?
Currently, no hedge funds are holding shares in PL:CTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Captor Therapeutics SA
Captor Therapeutics SA (CTX) is a biopharmaceutical company focused on developing innovative therapeutics in the field of oncology and autoimmune diseases. Utilizing its proprietary Targeted Protein Degradation (TPD) platform, the company aims to create novel therapies that selectively degrade disease-causing proteins, thereby addressing unmet medical needs. Captor Therapeutics operates primarily in the biotechnology sector, with a pipeline that includes several preclinical and clinical-stage compounds designed to revolutionize treatment paradigms in cancer and other serious conditions.
Technical Analysis
―
Ryvu Therapeutics SA
―
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
OncoArendi Therapeutics SA
―
Selvita SA
―